Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: Ken W who wrote (7499)	4/27/2005 12:19:55 PM
From: rrufff	Read Replies (1) \| Respond to of 23958

CTE +.01 Michael Szycher, PhD, to Deliver a Keynote Address at 2005 Society of Plastics Engineers Conference in Boston PR Newswire - April 27, 2005 12:12 WILMINGTON, Mass., April 27, 2005 /PRNewswire-FirstCall via COMTEX/ -- Michael Szycher, Ph.D., Chairman and Chief Executive Officer of CardioTech International Inc. (Amex: CTE) will be presenting a keynote address entitled: "Development of a Polymeric Coronary Artery Bypass Graft" at the Annual Technical Conference (ANTEC) of the Society of Plastics Engineers in Boston, May 2, 2005. The ANTEC (Annual Technical Conference) is sponsored by the Society of Plastics Engineers, and is the leading technical forum for providing cutting- edge technological issues and information pertinent to the needs of the plastics industry. Held only once a year, multiple peer-reviewed technical papers are presented providing plastics professionals unique inside access to proprietary research and findings. Dr. Michael Szycher was a member of the Thermedics team that developed the HeartMate, a left ventricular assist device (LVAD), and also founded PolyMedica Corporation. Thermedics and PolyMedica are manufacturers of innovative cardiovascular medical devices. He is the author of the best seller "Szycher's Handbook of Polyurethanes," and is the author of five other technical books on medical devices. In the presentation, Dr. Szycher will describe CardioTech's efforts to address the challenges of developing an "artificial saphenous vein" complete with living cells and collagen from the patient into a new therapeutic product. The CardioPass synthetic coronary artery bypass graft was designed to mimic the human saphenous veins in biomechanical properties. The microporosity of the polyurethane graft encourages cellular ingrowth, leading to collagenization of the synthetic structure. Any surgeon should be able to implant these grafts without any additional training, since the surgical implantation protocol is identical to current procedures that have been in use for decades throughout the world. The graft is currently targeted for "no option" patients, who have had previous failed bypass operations and are in need of a "re-do" procedure. "This conference offers a unique opportunity to come together with a diverse group of experts in polymer chemistry, medical marketing and industry executives," said Dr. Szycher. "I look forward to representing CardioTech in a discussion on how polymer technology and medical device manufacturing can work together to accelerate the translation of polymer science to clinical reality." CardioTech believes that this Release contains forward-looking statements that are subject to risks and clinical trial uncertainties. Such statements are based on management's current expectations and are subject to factors that could differ materially from the forward-looking statements. Please refer to CardioTech's SEC filings. For more information, please contact: Michael Szycher, Ph.D., MBA CEO 978-657-0075 SOURCE CardioTech International Inc. Michael Szycher, Ph.D., MBA, CEO of CardioTech, 978-657-0075 prnewswire.com Copyright (C) 2005 PR Newswire. All rights reserved.